Healthcare

Psychedelics show promise in treating clinical depression: Study

By Breccan F. Thies
Published September 5, 2023 9:43pm ET
Add Washington Examiner on Google
Psychedelics show promise in treating clinical depression: Study
Psilocybin, the hallucinogenic compound in psychedelic mushrooms, has shown promise as a treatment for clinical depression, according to a study. The study, published in the Journal of the American Medical Association, found that a single 25-milligram dose of psilocybin coupled with psychological support showed “clinically significant sustained reduction in depressive symptoms and functional disability, without […]


Psilocybin, the hallucinogenic compound in psychedelic mushrooms, has shown promise as a treatment for clinical depression, according to a study.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

Drugs Health Mental Health PTSD research Science Washington D.C.